Journal
JOURNAL OF CONTROLLED RELEASE
Volume 279, Issue -, Pages 1-7Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2018.04.010
Keywords
Intra-tumoral implant; Local anti-cancer treatment; Promoter drugs; Orthotopic model of breast cancer; Paclitaxel; Dexamethasone
Funding
- United States-Israel Binational Science Foundation [2013/131]
Ask authors/readers for more resources
The effect of topical co-administration of promoter drugs with paclitaxel to increase anti-tumor effects of paclitaxel was investigated. Mice with orthotopic 4T1-Luc breast cancer received single intra-tumoral injection of a polymeric formulation with paclitaxel and a specific promoter drug. Several promoter drugs were evaluated, including: dexamethasone, losartan, nicotinamide, Azone, and oleic acid. Dexamethasone exhibited the highest effect on paclitaxel anti-tumor activity, in a dose-dependent fashion. However, this effect was accompanied by systemic effects of dexamethasone, and inability to prevent tumor metastasis to the lungs. Topical co-administration of promoter drugs with anti-cancer agents can enhance their anti-tumor effects. Further investigations are needed to identify the most efficient combinations of promoter and anti-cancer drugs, and their suitability for the clinical management of the breast cancer disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available